• Assembly Bio published a year-end earnings press release, reporting cash, cash equivalents and marketable securities of USD 248.1 million and saying its cash position is projected to fund operations into 2028.
• Collaboration revenue from Gilead rose 100% to USD 72.3 million, reflecting increased collaboration funding.
• Research and development expenses increased 15.9% to USD 64.81 million, largely driven by higher spending on the herpesvirus helicase-primase inhibitor program as ABI-1179 and ABI-5366 Phase 1b studies saw significant enrollment.
• Net loss attributable to common stockholders narrowed 84.8% to USD 6.1 million, while loss from operations narrowed 73.3% to USD 12.12 million.
• Pipeline updates included licensing the herpesvirus HPI program (ABI-5366 and ABI-1179) to Gilead for a net USD 35 million option fee, and a Phase 2 study initiation for ABI-6250 in chronic hepatitis delta virus anticipated by end of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603191605PRIMZONEFULLFEED9675246) on March 19, 2026, and is solely responsible for the information contained therein.